ZappRx, the US-based developer of an online drug prescription platform, has completed a $25m series B round featuring SR One and GV, respective subsidiaries of pharmaceutical firm GlaxoSmithKline and internet technology group Alphabet.
Qiming US Healthcare Fund, part of China-based venture capital group Qiming Venture Partners, led the round, and managing partner Mark McDade, will join ZappRx’s board of directors.
ZappRx has built a secure cloud-based platform that streamlines the process of prescribing specialty drugs, cutting down on the paperwork for physicians and enabling them to more efficiently manage their patients’ condition.
The funding will support the commercial launch of ZappRx’s platform, which will also supply data to speciality pharmaceutical providers.
Zoë Barry, founder and chief executive of ZappRx, said: “We are excited to have top tier investors Qiming US, SR One and GV stand behind our product and our vision to transform specialty drug prescribing.”
SR One led ZappRx’s $5.6m series A round in 2015, investing alongside VC firm Atlas Venture, the two having provided $1m of seed capital for the company the previous year. ZappRx has now raised $41m in total, it told TechCrunch.